HSE South West has launched the country’s first home-administered Herceptin initiative at Cork University Hospital, allowing HER-2 positive breast cancer patients to receive their maintenance therapy at home rather than traveling to a clinical setting.
How the Herceptin in the Home Programme Works
Herceptin serves as a maintenance drug prescribed following surgery, chemotherapy, or radiotherapy. Patients typically receive the medication via injection every three weeks for life to target HER-2 positive breast cancer cells, stopping them from spreading and assisting the body in destroying them. Under the new initiative at Cork University Hospital (CUH), eligible patients can forgo regular hospital visits for these maintenance injections, receiving them safely in a home environment instead.
Did you know? Designed to combat HER-2 positive breast cancer, Herceptin is a crucial medication that saves lives by halting cellular proliferation and empowering the body’s immune defenses to eliminate those cells.
Clinical Goals and Regional Expansion Plans
Clinical nurse specialist and project lead Helen O’Shea stated that the primary objective is to improve access and convenience for patients. She pointed out that the project will additionally guide the broader creation of home-based and community-backed systemic anti-cancer treatment pathways throughout Cork and Kerry. Professor Dearbhaile Collins, clinical director of cancer services at HSE South West, emphasized the personal toll of hospital-based care.
“Living with cancer is incredibly tough, and spending hours in a hospital adds a lot of stress,” Professor Collins said, adding that her ambition is to grow and roll out the service region-wide and potentially apply the model to other cancer types.
Impact on Hospital Capacity and Patient Freedom
CUH pharmacist Katie Cooke highlighted the operational benefits of the decentralized care model. According to Cooke, bringing the drug directly into homes gives patients their time back and makes treatment safer and more comfortable.
“It is a first for Ireland. Not only is it giving patients freedom back, but it is also freeing up staff and patient capacity at CUH, so we can care for more patients faster,” Cooke said. The National Cancer Control Programme supports the initiative, reflecting a shared institutional commitment to advancing patient-centered cancer care models.
Frequently Asked Questions
What is Herceptin used for?
Herceptin is a maintenance drug used to treat HER-2 positive breast cancer by stopping cells from spreading and helping the body destroy them.
Who is eligible for the home administration programme?
The programme is currently being offered by the Cancer Centre at CUH for eligible patients receiving Herceptin maintenance therapy.
How often is Herceptin administered?
Patients typically receive the drug via injection every three weeks following initial treatments such as surgery, chemotherapy, or radiotherapy.
Will this programme expand to other regions?
Health officials have expressed an ambition to grow and roll out the service across Cork and Kerry, with potential for application to other cancer types in the future.
Stay Informed on Healthcare Innovations
Subscribe to our newsletter to receive the latest updates on medical advancements, hospital services, and patient care initiatives across the region.
Keep reading